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Uveal melanoma, in spite of its rarity, represents the most common primitive intraocular
malignant neoplasm of the adults; it affects choroid, ciliary bodied and iris and remains
clinically silent for a long time, being accidentally discovered by routine ophthalmic exams.
Prognosis of uveal melanoma is poor and frequently characterized by liver metastases,
within 10–15 years from diagnosis. Autophagy is a multi-step catabolic process by which
cells remove damaged organelles and proteins and recycle nutrients. It has been
hypothesized that in early stages of tumorigenesis autophagy has a tumor suppressor
role while, in more advanced stages, it may represent a survival mechanism of neoplastic
cells in response to stress. Several proteins related to autophagy cascade have been
investigated in numerous subtypes of human cancer, with overall controversal results. In
this paper we studied the immunohistochemical expression of 3 autophagy related
proteins (Beclin-1, p62 and ATG7) in a cohort of 85 primary uveal melanoma treated by
primary enucleation (39 with metastasis and 46 non metastatic) and correlated their
expression with clinico-pathological parameters and blood vascular microvessel density,
in order to investigate the potential prognostic role of autophagy in this rare neoplasm. We
found that high immunohistochemical levels of Beclin-1 correlated with a lower risk of
metastasis and higher disease-free survival times, indicating a positive prognostic role for
Beclin-1 in uveal melanoma. No statistically significative differences regarding the
expression of ATG7 and p62 between metastatic and non metastatic patients
was detected.
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Although uveal melanoma (UM) is traditionally considered a
rare tumor, it is the most frequent primitive intraocular
malignancy of the adults and the second most frequent
melanoma not associated with epithelial structures (1–3). UM
is extremely rare in children in whom it recognizes a congenital
origin and is often diagnosed in advanced stages of disease with
extraocular spreading (4). Choroid is the most common
intraocular site involved, followed by ciliary bodies and, less
frequently, iris (3). The occurrence of uveal melanoma is 200
times higher in Caucasians, Fitzpatrick phototypes I-II (scores 1
to 13), than in the black population (5, 6). Nevertheless, the
ultimate role of UV-B and UV-A exposure as a risk factor for
uveal melanoma is still to be fully clarified. Recent reports
evidenced that the use of sun-tanning devices is a well-
recognized risk factor for uveal melanoma, as opposed to
sunlight exposure, hypothesizing that this phenomenon could
be correlated to the inability of artificial tanning to increase
systemic level of vitamin D3 (7). Presence of choroidal nevus,
syndromic/congenital diseases such as cutaneous dysplastic
nevus syndrome, oculo-dermal melanocytosis (Ota nevus) and
type 1 neurofibromatosis, have traditionally been included
among risk factors associated with the onset of UM (8).
Sudden retinal detachment is the most frequent presentation of
disease; however, this tumor is often clinically silent for a long
time, and it is frequently accidentally discovered by routine
ophthalmic exams (9, 10). Although several steps have been
made in the knowledge and treatment of this neoplasm, the
prognosis of UM remains poor with about half of patient
developing distant metastases, especially in the liver, within 10-
15 years from primary enucleation (10).
To date, the peculiar interplay between the molecular routes
that underlie the clinical behavior of UM has still to be fully
clarified (11). Deregulation of cell death programs is a hallmark of
cancer development, progression, and resistance to therapies (12,
13). A negative regulation of pro-apoptotic molecules by
oncogenic signaling (14) and the involvement of several anti-
apoptotic proteins involved in the regulation of extrinsic and
intrinsic apoptotic pathways have been largely reported in
melanoma (15, 16). Recently, also non-apoptotic, autophagy-
dependent cell death pathways necroptosis, ferroptosis,
pyroptosis, and parthanatos have been found involved in skin
melanoma cell response to therapy. Melanoma cells use autophagy
to counteract drug activity and tumor microenvironment drug-
induced changes, conditioning clinical outcome and resistance to
target therapy and immunotherapy (17, 18).
Autophagy is a catabolic process through which damaged
organelles and proteins are removed and nutrients recycled by
cells (19, 20). During the initiation and development of tumors,
autophagy is likely to mainly play a tumor suppressor role while, in
well-established cancers, it may constitute a survival mechanism in
response to stress (21). Up to now, its role in cancer remains
controversial, particularly for its relationship with prognosis. Three
main dynamic autophagy pathways exist: chaperone-mediated
autophagy (CMA), microautophagy, and macroautophagy (22).Frontiers in Oncology | www.frontiersin.org 2CMA is a selective multistep autophagy pathway that modulates
the turnover of soluble cytosolic proteins, delivering them directly to
lysosomes for degradation, without formation of vesicles (23).
Microautophagy leads to the degradation of intracellular proteins
and organelles directly engulfed by lysosomes or endosomes. The
extent and role of microautophagy in mammalian cells have been
yet poorly understood (24). Macroautophagy is a multistep process
characterized by the formation of autophagosomes (double-
membraned coated vesicles), that fuse with the membrane of
lysosome, that degrade and recycle their contents (25). The
macroautophagic process is regulated by six autophagy-related
(ATG) protein classes and/or complexes (26). Autophagy cannot
be detected in routine hematoxylin and eosin-stained and formalin-
fixed and paraffin-embedded tissues. Biomarkers detection by IHC
constitutes at present the best way to examine this process on
routine tissue sections (27). Many of more than 30 autophagy-
related genes (ATG) encoded proteins in human cells are detectable
by immunohistochemistry (28, 29).
In this study, we choose to immunohistochemically
investigate the expression of three proteins involved in the
macroautophagic step of the autophagy cascade, Beclin-1, the
autophagy-related gene 7 (ATG7), and p62, in a cohort of 62
patients affected by UM at different clinical stage.
BECN1 (Beclin-1) is the mammalian ortholog of yeast
autophagy-related gene 6 (ATG6), which induces autophagosome
formation. The human Beclin-1 gene is located on chromosome
17q21, and in the early stages of autophagy interacts with various
cofactors forming a complex necessary for the recruitment of other
ATG proteins and for the progression of the autophagic process
(29–32). The evidence that Beclin-1 expression is monoallelicaly
suppressed in some human breast, ovarian and prostatic cancer cell
lines, suggests that it acts as a tumor suppressor gene (30–32). A
decreased expression of Beclin-1 at mRNA and protein levels has
been found in human brain tissues (33) and in estrogen receptor-
negative, HER2-positive breast cancer, in which the reduced
BECN1mRNA expression has been found associated with poor
prognosis (34). In addition, upstream positive regulators of Beclin-1,
such as UV radiation and Bax interacting factor-1 (Bif-1), have been
found downregulated in several types of human cancers (35, 36) and
an increased tumor incidence has been reported in Beclin1
heterozygous mice.
All these evidences support the tumor-suppressive function of
macroautophagy (37). By converse, macroautophagy can be
induced by cancer therapy, and in this eveniences, it has been
found to support tumor cell survival, suggesting the gain of
oncogenic function (38, 39). The role of macroautophagy in
tumorigenesis, then, looks very complex and controversial, with
sensible variation among different tumor types and/or different
tumor stage (40). ATG7, located on chromosome 3p25.3,
encodes an E1-like activating enzyme essential for cytoplasmic
to vacuole transport (41). The encoded protein also has
modulating function on p53-dependent cell cycle pathways
during sustained metabolic stress phases (41). The expression
of ATG7 has been recently found to correlate with resistance to
anticancer drugs (42). p62 acts as an adaptor protein, through
the binding of ubiquitylated protein aggregates and the deliver toNovember 2020 | Volume 10 | Article 589849
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triggered to counteract oxidative stress has been reported in
melanoma cells exposed to ultraviolet A (UVA) (45).
The aim of this paper is to investigate any relationship among
the expression of these three macroautophagy-related proteins
and clinical-pathological parameters and behavior of UM.MATERIALS AND METHODS
Clinical data and histological samples of 85 patients affected by
primaryUM,whounderwent primary enucleation at the EyeClinic
of bothUniversity ofCatania andUniversity ofNaples “Federico II”
during the ten years up to October 2019, were retrospectively
analyzed. All cases were not eligible for non-surgical procedures,
such as plaque brachytherapy or proton beam radiotherapy. The
research protocol for this retrospective study was approved by our
Institutional Medical Ethical Committee (according to the ethical
guidelines of theDeclarationofHelsinki). Paraffin-embedded tissue
samples from each case were selected from the surgical pathology
archive of the Sections of Anatomic Pathology, Department G.F.
Ingrassia, University of Catania, and Department of Advanced
Biomedical Sciences, University of Naples “Federico II”. The
following exclusion criteria were used for the selection of cases: i)
paraffin blocks in which there was not enough tissue to get
additional slides for immunohistochemistry; ii) representative
neoplastic tissue was absent; iii) necrosis was the major
component of the tumor blocks; iv) the tumor underwent
preoperative radiotherapy. Five or more sections were obtained
fromeachparaffinblock. Fivepathologists (GB,LP,DR,SSandRC),
not aware of the clinical and prognostic data of the corresponding
patients, evaluated all histological specimens separately.
Discrepancies in the evaluation were resolved by consensus.
The cohort of cases included 39 UMs with metastasis and 46
non metastatic UMs. We collected the following clinical data:
tumor size and location, determined with standard methods,
such as ophthalmoscopy and A and B scan ultrasonography, and
onset of metastases, evaluated with physical examination, liver
ultrasound and total body computed tomography (CT). The A-
scan ultrasound is a mono-dimensional amplitude modulation
scan, mainly used in ophthalmology to study routine visual
disorders and/or to investigate the size and ultrasound features
of intraocular masses; conversely, B-scan ultrasound refers to a
two-dimensional, cross-section brightness scan, that, if
combined to A-scan imaging, allows to get more details about
the tumor, including exact anatomic site, borders, shape, and
size, and to obtain a more detailed preoperative diagnosis.
Evaluation of Blood Vascular Microvessel
Density (MVD)
MVD was evaluated by five pathologists (GB, LP, DR, SS and
RC), who identified vascular hotspots on immunohistochemical
sections of the UM cohort stained for anti-CD31 antibody by a
light microscope at 4× and 10× magnifications, as previously
described (46). MVD consisted of the amount of vessels per mm2
(conversion factor: 1 mm2 = 4 high power fields (HPFs) at 40×Frontiers in Oncology | www.frontiersin.org 3magnification inside vascular hotspots. Areas with ≥50 of viable
tumor cells were considered usable for counting; Presence of
diffuse necrotic, hemorrhagic and totally pigmented areas were
considered as exclusion factors. Each CD31+ endothelial cell
and/or lumen for long branched vessels were counted. Positive
staining of small clusters of ≥2 endothelial cells was assessed as
one single vascular structure. MVD levels were considered high if
> the median value, low if < the median value.
Immunohistochemistry
Sections were treated for immunohistochemical analyses with
standard methods (47), using the streptavidin/biotin-based
system for immunoperoxidase; briefly, after appropriate
deparaffinization and pre-treatments, sections were incubated for
30min at 37°Cwith primary polyclonal rabbit anti-human antisera
against Beclin-1 (working dilution 1:250; Abcam, Cambridge, MA,
USA), p62 (workingdilution1:200;Abcam,Cambridge,MA,USA),
ATG7 (working dilution 1:100; Abcam, San Francisco, CA, USA)
and with primary monoclonal mouse anti-human antiserum
against CD31 (JC70A; working dilution 1:40; DAKO, Glostrup,
Denmark). The secondary biotinylated antibody was applied for
30 min at room temperature, followed by the streptavidin–biotin–
peroxidase complex for a further 30 min at room temperature. The
immunoreactionwasvisualizedby incubating the sections for 4min
in a 0.1% 3,3’-diaminobenzidine (DAB) and 0.02% hydrogen
peroxide solution (DAB substrate kit, Vector Laboratories,
CA, USA).
Evaluation of Immunohistochemistry
p62 and Beclin-1 were immunoexpressed both in the cytoplasm and
in the nucleus of neoplastic cells, while ATG-7 only showed
cytoplasmic staining. Negative controls were additionally used by
omitting the primary antibody. Intensity of staining (IS) was scored
onascaleof 0–3 (47), as follows: absenceof staining=0,weak staining
= 1, moderate staining = 2, strong staining = 3. The percentage of
immunopositive cells (Extent Score, ES) was graded by five
groups (47): <5% (0); 5–30% (+); 31–50% (++); 51–75% (+++),
and >75% (++++). Counting was performed at 200× magnification.
The intensity reactivity score (IRS) was obtained by multiplying IS
andES (47): IRS<6was interpretedas lowexpression(L-IRS), IRS>6
as high expression (H-IRS).
Statistical Analysis
The rates of high and low levels of beclin-1, p62, ATG7
expression in melanoma of patients with and without
metastasis were non parametrically compared by chi-square
test. Agreement among observers was tested by Cohen K.
Univariate and multivariate analyses, based on a Cox
proportional hazards regression model (time free from metastasis
as outcome), were performed; gender, age, melanoma location
(choroid or ciliary body), temporal or nasal location, cells type
(epithelioid, spindle cells or mixed), echographic parameters
(height, greatest diameter), and expression level (low and high)
of beclin-1, p62, ATG7 andMVDwere all included in this model. If
a predictor had a P value <0.15 (cut off) in the univariate analysis, it
was included in the multivariate one. Survival analysis according to
beclin-1, p62, ATG7 and MVD expression levels (high and low)November 2020 | Volume 10 | Article 589849
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by log-rank (Mantel-Cox) test. P values < 0.05 were considered as
statistically significant.
RESULTS
Clinico-Pathological Features of Uveal
Melanomas
Eighty-five patients were part of the study (44 males; 41 females);
median age was 67 years (range 29–85). Choroid was the only
affected site in 64 cases, while choroid and ciliary body were
simultaneously involved in 21 cases. Extrascleral extension was
identified in 3 cases. Histologically, 20 cases were diagnosed as
epithelioid cell, 25 as spindle cell, while 40 cases as mixed
epithelioid and spindle cell UMs. According to the “TNM
classification of malignant tumors”, pathological T stage was:
pT1a in 15 patients, pT1b in 4 patients, pT2a in 45 patients, pT2b
in 16 patients, pT2d in 1 patient, pT3a in 21 patients, pT3b in 10
patients, pT3d in 1 patient, pT4a in 8 patients, pT4b in 8 patients
and pT4d in 1 patient. Liver metastases were present in 39
patients. Median follow-up period was 58 months (range 8–138).
Among the 46 non metastatic patients, 25 were males and 21
females;median agewas 64 years (range 19–84).Out of 39metastaticFrontiers in Oncology | www.frontiersin.org 4patients, 19weremales and20 females;median agewas 71 (range 50–
85). 25/39patientswithmetastases diedduring the follow-up time for
disease progression (Figures 1, 2). No significant difference was seen
in median age, location of the melanoma (choroid or choroid/ciliary
body), tumor thickness, histological type, extrascleral invasion and
pathological T stage betweenmetastatic and nonmetastatic patients;
UMswith greatermedian largest diameter (15.4mmvs 12.4mm, p=
0.009), lower median Beclin-1 expression (6 vs 8, p = 0.018), lower
median p62 expression (6 vs 8, p = 0.025), lower median ATG7
expression (6 vs 9, p = 0.026) and higher median MVD levels (54 vs
26, p < 0.001) were observed in metastatic patients, who also
presented lower median disease free survival (25 months vs 73




Factors and MVD in Uveal Melanomas
In the overall cohort of patients included in the study (n = 85) the
median Beclin-1 value was 8. Beclin-1 expression was high in 55
Iand low in 20 UMs (Figures 4A, B). Among 46 primary non
metastatic UMs, only 10/46 cases (21.7%) showed L-IRS, while
the other 36 UMs showed H-IRS (78.3%) (Fisher’s exact test, p =FIGURE 1 | Tumor parameters, disease free time, follow-up, beclin-1, p62 and ATG7 expression and MVD in primary uveal melanoma without metastasis.November 2020 | Volume 10 | Article 589849
Broggi et al. Autophagy Assessment in Uveal MelanomaFIGURE 2 | Tumor parameters, disease free time, follow-up, beclin-1, p62 and ATG7 expression and MVD in primary uveal melanoma with metastasis.FIGURE 3 | Median (range) of demographics, tumor parameters, disease free time, follow-up, beclin-1, p62, and ATG7 expression and MVD in primary uveal
melanoma without and with systemic metastasis.Frontiers in Oncology | www.frontiersin.org November 2020 | Volume 10 | Article 5898495
Broggi et al. Autophagy Assessment in Uveal Melanoma0.007, Figure 5). In 39 primary metastatic UMs 19/39 cases
(48.7%) had H-IRS, while L-IRS was found in 20/39 UMs
(51.3%) (Fisher’s exact test, p = 0.007, Figure 5).
Among the 85 patients studied, the median p62 value was 6.
p62 levels were high in 61 and low in 24 cases (Figures 6A, B).
Among metastasis-free patients, only 9/46 cases (19.6%) showed
L-IRS, while H-IRS was observed in the remaining 37/46 cases
(80.4%) (Fisher’s exact test, p = 0.089, Figure 5). 15/39 metastatic
patients (38.5%) showed L-IRS, while 24/39 (61.5%) had H-IRS
(Fisher’s exact test, p = 0.089, Figure 5).Frontiers in Oncology | www.frontiersin.org 6In the whole group of UMs, the median ATG7 value was 8.
ATG7 immunoexpression was high in 51 patients and low in 34
(Figures 7A, B). Out of the 46 patients without metastatic
disease, ATG7 L-IRS was found only in 13/46 non metastatic
UMs (28.3%), while 33/46 (71.7%) had ATG7 H-IRS (Fisher’s
exact test, p = 0.026, Figure 5). 21/39 metastatic patients (53.8%)
showed ATG7 L-IRS, while the remaining 18/39 (46.2%) ATG7
H-IRS (Fisher’s exact test, p = 0.026, Figure 5).
Out of 85 patients studied, the median MVD value was 34
(range 11–78). MVD levels were high in 43 and low in 42 cases.FIGURE 4 | High (A) and low (B) expression of Beclin-1 in uveal melanoma. (Immunoperoxidase stain; original magnifications 100×).FIGURE 5 | Number of uveal melanoma (with and without metastasis) with low and high beclin-1, p62, and ATG7 expression and MVD (n/mm2).November 2020 | Volume 10 | Article 589849
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while high in the remaining 13/46 cases (28.3%) (Fisher’s exact
test, p < 0.001, Figure 5). 30/39 metastatic patients (76.9%)
showed high MVD, while only 9/39 (23.1%) showed low MVD
(Fisher’s exact test, p < 0.001, Figure 5).
Factors related to the presence of metastasis at univariate
analysis on a Cox proportional hazards regression model were:
age (p=0.011), diameter (p=0.044), epithelioid cell type
(p=0.017), pT stage (p=0.023), and beclin-1 level (p=0.001),
p62 level (p=0.079), ATG7 (p=0.002) and MVD (p<0.001).
At multivariate analysis MVD (p=0.009), epithelioid cell type
(p=0.014), diameter (0.026) and beclin-1 level (p=0.035)
were significant.
No correlation was found between histological type and
beclin-1 expression (Spearman’s rho p=0.289), p62 expression
(Spearman’s rho p=0.568), ATG7 (Spearman’s rho p=0.127), and
MVD (Spearman’s rho p=0.087).
Figure 8 shows the results of Kaplan–Meier survival analyses in
patients with uveal melanomas with low and high beclin-1
expression. The mean survival time free from metastasis (SE, with
95%CI) estimated were respectively: 50.7 (9.1) (CI: 32.9 to 68.5) and
113.9 (9.9) (CI: 94.5 to 133.4). The log-rank test showed a significant
difference (p=0.001) between the two groups.
Figure 9 shows the results of Kaplan–Meier survival analyses in
patients with uveal melanomas with low and high p62 expression.Frontiers in Oncology | www.frontiersin.org 7The mean survival time free from metastasis (SE, with 95% CI)
estimated were respectively: 66.8 (12.3) (CI: 42.7 to 90.9) and 104.9
(9.8) (CI: 85.6 to 124.1). The log-rank test showed no significant
difference (p=0.073) between the two groups.
Figure 10 shows the results of Kaplan–Meier survival analyses in
patients with uveal melanomas with low and high ATG7 expression.
The mean survival time free from metastasis (SE, with 95% CI)
estimated were respectively: 54.8 (9.7) (CI: 35.8 to 73.9) and 114.6
(10.1) (CI: 94.9 to 134.3). The log-rank test showed a significant
difference (p=0.002) between the two groups.
Figure 11 shows the results of Kaplan–Meier survival analyses in
patients with uveal melanomas with low and highMVD expression.
The mean survival time free from metastasis (SE, with 95% CI)
estimated were respectively: 50.0 (7.4) (CI: 35.5 to 64.6) and 134.3
(10.0) (CI: 114.7 to 153.9). The log-rank test showed a significant
difference (p<0.001) between the two groups.
The results of the correlation analysis between Beclin-1 IRS,
MVD values and DFS are displayed in Figure 12.DISCUSSION
Due to its apparent “indolence” and slow progression, UMmay be
considered as a tumor with ambiguous clinical course, marked by
the occurrence of liver metastases in almost all cases even after 10–FIGURE 6 | High (A) and low (B) expression of p62 in uveal melanoma. (Immunoperoxidase stain; original magnifications 100×).November 2020 | Volume 10 | Article 589849
Broggi et al. Autophagy Assessment in Uveal MelanomaFIGURE 7 | High (A) and low (B) expression of ATG7 in uveal melanoma. (Immunoperoxidase stain; original magnifications 100×).FIGURE 8 | Kaplan–Meier survival analyses in patients with uveal melanomas with low and high Beclin-1 expression.Frontiers in Oncology | www.frontiersin.org November 2020 | Volume 10 | Article 5898498
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histopathological factors have been traditionally included among
the ones negatively affecting the prognosis of UM: advanced age
and stage at diagnosis, male gender, tumor thickness and largest
diameter, ocular/cutaneous melanocytosis, localization to ciliary
bodies, extrascleral invasion. By a morphological microscopic
point of view, the prevalence of an epithelioid cytotype (48),
high mitotic index and tumor associated angiogenesis (expressed
as MVD), necrosis, are considered factors linked to a more
aggressive tumor behaviour. As well, tumor infiltrating
lymphocytes and/or histiocytes (49) and cytogenetic factors
including monosomy 3, chromosome 8q-gain or 8p-loss,Frontiers in Oncology | www.frontiersin.org 10chromosome 1p-loss, chromosome 6q-loss, and high expression
of insulin-like growth factor-1 receptor (IGF-1R) (50), also
contribute to the definition of the class risk of each case of UM.
In particular, the reduction/loss of the nuclear immunostaining for
the BRCA1 associated protein-1 (BAP-1), reflecting the presence
of inactivating mutations of the corresponding gene, represents a
poor prognostic factor for of UM (51, 52).
We previously identified the immunohistochemical
expression of proteins, such as RKIP, pRKIP, ADAM10,
ABCB5, SPANX-C, and MacroH2A, as possible useful
prognostic markers in UM (47, 53–56). However, despite the
efforts of the scientific community and the increase of possibleFIGURE 11 | Kaplan–Meier survival analyses in patients with uveal melanomas with low and high MVD count.FIGURE 12 | Correlation analysis between beclin-1 IRS, MVD values and DFS.November 2020 | Volume 10 | Article 589849
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advanced disease are yet dismal, so the identification of new
prognostic and predictive tissue markers for UM is still an
urgent need.
Autophagy looks to act as “double-edged sword” in cancers
(57), either contributing to the induction of apoptosis in
aberrantly proliferating or damaged cells in early tumor stages,
or contributing to the survival of advanced cancer cells upon
hostile events, as hypoxia and reduced availability of nutrients, or
antineoplastic drugs.
Beclin-1, has a central role in the autophagic process as a
major member of the macro-autophagic phase, and ranks above
the most studied proteins. A great variability in the expression of
this macroautophagy-related protein in human tumor tissues has
been documented, sometimes with frankly divergent results. The
loss/reduction of Beclin-1 expression has been shown to be
closely related either to a better survival, as in endometrial,
renal, gastric and colorectal cancers (29, 58–60), or to a reduced
disease-free survival (DFS) and poorer prognosis in ovarian
cancer patients receiving combined therapy with platinum and
taxanes (61), and in a cohort of non-small cell lung cancer
(NSCLC), in which the expression of the protein showed an
independent positive prognostic factor (62). In squamous cell
carcinomas of the uterine cervix the overexpression of Beclin-1
has been reported to inhibit metastatic progression in vitro (63),
and in non-Hodgkin lymphomas (NHL), the increased
expression of Beclin-1 has been found related to an increase in
LC3-positive autophagic vacuoles and a better outcome of
patients after chemotherapy (64). In melanocytic skin lesions, a
gradual decrease of cytoplasmic expression of Beclin-1 has been
found correlated with the progressive gain and increase of
malignancy (65). The immunohistochemical expression of
Beclin-1 has been detected, in fact, in about 100% of benign
nevi and 86.4% of dysplastic nevi, decreasing to 54.3% in primary
melanomas and up to 26.7% in melanoma metastases. Further
studies showed instead that vemurafenib reduced miR-216b level
resulting in upregulation of Beclin-1 (66), has been reported as a
mechanism of drug-induced autophagy, allowing vemurafenib-
resistant melanoma cells to employ autophagosomes to secret
ATP to enhance cell migration and invasion (67).
The prognostic role of autophagy and Beclin-1 in UM has
been investigated by Giatromanolaki et al. (68), who found either
the overexpression and the reduced expression of BECN1
associated with poor prognosis.
Our results indicated a prognostic role of Beclin-1 in UM, with a
lower risk of metastasis and higher disease-free survival times
observed in UM cases with higher immunohistochemical
expression of the protein. By converse, our population of UM
with low expression of Beclin-1 was characterized by a higher
metastatic risk. In our study, no statistically significative difference
in the immunohistochemical expression of ATG7 and p62 proteins
between metastasizing and non-metastasizing primary UM was
detected. In our series of cases, the expression of these two macro-
autophagy related proteins didn’t show any predictive value for
metastatic risk of UM. Among the autophagy-related proteins
analyzed in our study, then, only Beclin-1 resulted promising as aFrontiers in Oncology | www.frontiersin.org 11new possible immunohistochemical marker able to predict
metastatic risk in patients with primary UM.
Some considerations have to be made, before any conclusion
at this regard may be got. To date, there is still the lack of robust
markers, improved staining protocols, and standardized
interpretation to measure autophagy activity in archived tissue,
and we must interpret our data with caution, strictly integrating
them with clinical and follow-up data (22).
New specific markers identifying the core autophagy
components and its upstream and downstream regulators, and
the identification of specific gene “signatures” are needed for a
more accurate assessment of the autophagic activity in FFPE
tumor samples, at diagnostic and/or prognostics level, and to
predict response to new autophagy-targeted treatment.
Moreover, controversies remain regarding whether to inhibit
or enhance autophagy in cancer, considering that, besides
activation of endocytosis, the deregulation of autophagy-related
genes has been associated also with cell death pathways and
DNA repair responses (non-autophagy functions) (69, 70).
Nevertheless, our finding of a strict correlation between Beclin-
1 expression and the clinical outcome of UM support the idea
that alteration in autophagy may be a particularly attracting
targetable way to treat UM progression, as it has been proposed
for skin melanoma. In cutaneous melanoma, even considering
the large patient-to-patient variability of drug resistance
mechanisms, non-apoptotic cell death has been considered as
alternative therapeutic target when induction of apoptosis is
impaired (71).
In addition, the finding of an altered expression of Beclin-1 in
our study population sounds particularly attractive, if we
consider that recent evidence suggests that alterations in
autophagy may be a major mechanism of tumor escape from
immune surveillance also by interfering with signaling pathways
in tumor and immune cells (72) and autophagy-associated cell
death has emerged as a key immunogenic mechanism able to
potentiate tumor response to therapy in several human
malignancies and in skin melanoma (29, 58–68). In particular,
recent studies indicate that targeting autophagy in melanoma
cells in combination with immunotherapy could gain results in
promoting tumor regression, and autophagy has been shown to
act a pivotal role in dendritic cell and T-lymphocyte infiltration
(73, 74) in immune-competent animal models. These
observations sound particularly interesting, that targeting
autophagy could offer a new chance for UM patients non-
responder to targeted and immunotherapeutic protocols active
on most of human solid malignancies.
Further considerations emerge, in addition, from the analysis
of several existing data indicating additional non-autophagic
roles of beclin-1 expression in cancer. Besides inducing
autophagy, this protein has been documented to be involved in
parallel in growth signaling pathways AKT (protein kinase B)
and ERK (kinase regulated by extracellular signals). It is therefore
plausible that the increased expression of Beclin-1 inhibits these
signaling pathways, limiting neoplastic growth (75).
Likewise, interesting consideration could derive from the
analysis of the possible correlation between the expression ofNovember 2020 | Volume 10 | Article 589849
Broggi et al. Autophagy Assessment in Uveal MelanomaBeclin-1and uveal melanoma angiogenesis. As before outlined,
increased angiogenesis, expressed as micro-vascular density
(MVD) evaluated immunohistochemically, has been associated
with poor prognosis (high metastasis and mortality rate) in uveal
melanoma (76, 77). This finding it is not surprisingly, if we
consider that UM metastasizes solely via the haematogenous
route. In a previous study, we found that the chemokine receptor
CXCR4, a prognostic factor in cutaneous melanoma being
involved in angiogenesis and metastasis formation, is
commonly expressed in uveal melanoma and correlates to
the epithelioid-mixed cell type (78). In addition, Brouwer NJ
and colleagues analyzed the correlation between several
angiogenesis-related cytokines and the development of tumor
vessels of primary UM, founding that a high MVD is associated
with an increased expression of angiopoietin 2, Von Willebrand
Factor, and a decreased expression of vascular endothelial
growth factor B (VEGF-B) (79). It has been found that the
expression of endothelial growth factors (VEGF, MMP-9) is
negatively modulated by high levels of Beclin-1 (80).
Basing on this finding, the results concerning Beclin-1
expression in our study population lead us to hypothesize that
a similar scenario could have important effects on tumor
angiogenesis in UM. This could at least in part address the
many still unanswered questions concerning the complex
interplay between the regulation angiogenesis pathways and its
correlation with UM biological behavior.
The mechanisms by which Beclin-1 negatively modulates
tumor growth are not fully understood. A recent study
outlined that Beclin-1 may interact also with members of the
bcl-2 protein, acting as a tumor suppressor protein (81), and this
finding could explain, at least partially, its positive prognostic
role in different types of human cancers. The conflicting data in
literature indicate in addition different patterns and roles of
Beclin-1 expression depending on neoplastic cell types.
To date, many concerns need to be still overcome, to
fully clarify the ultimate role of Beclin-1 expression in cancerFrontiers in Oncology | www.frontiersin.org 12progression and cancer response to therapy in UM, and a further
study on larger, multi-institutional series of cases is currently in
progress to definitively validate our results. Nevertheless, the
results of our study indicate that a relationship between
the immunohistochemical expression of Beclin-1 and the
biological behavior of UM exists, and this could open up new
prognostic and therapeutic strategies for this peculiar, deadly
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